ArticleBMC neurology2026
Short-term course of the neuropsychological profile in myotonic dystrophy type 1: a 12-month longitudinal study.
Article in BMC neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Cognitive decline over time in myotonic dystrophy type 1: a systematic review of longitudinal studies.Frontiers in neurology · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundMyotonic dystrophy type 1 (DM1) is a complex, multisystemic neuromuscular disorder that affects various systems, including the muscular and central nervous systems. The natural history of DM1 includes a cognitive decline over time across multiple cognitive functions. However, the course of the cognitive profile remains unknown over short follow-up intervals. The study aimed to document the course of the neuropsychological profile in adults with DM1 over 12 months using classic paper-pencil tests and computerized cognitive tests from the Cambridge Neuropsychological Test Automated Battery (CANTAB®).
methodsAdult participants with a genetically confirmed diagnosis of juvenile, adult, or late-onset phenotype of myotonic dystrophy type 1 (DM1) underwent a battery of traditional paper-and-pencil tests alongside four assessments from the computerized cognitive battery, CANTAB®. Cognitive functions were evaluated at baseline and at two follow-up points, each 6 months apart. Repeated measures ANOVAs were conducted, followed by post hoc analyses to compare results across the different time points. Significant changes were interpreted in relation to the measurement error.
resultsForty-four participants with DM1 (m = 45.5 ± 11.2 years) were assessed (50% juvenile, 38.6% adult, 11.4% late-onset). Results showed an overall stability in cognitive functions at both 6 and 12 months. However, verbal memory (California Verbal Learning Test) and multitasking skills (CANTAB®) exhibited an improvement outside of the measurement error, likely reflecting a learning effect.
conclusionsShort-term progression studies are essential to improve trial readiness by documenting the best outcome measures to assess treatment effectiveness and gathering a comprehensive overview of the cognitive profile progression in DM1.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.